SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as community members discuss its upcoming presentation with NVIDIA and potential catalysts, including One Amazon. The discussion includes opinions on contracts and the company's overall direction. Some are focused on potential short squeezes.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending upwards, fueled by optimism around potential Federal Reserve rate cuts and excitement surrounding the company's energy storage business, including the Megapack 3 and Megablock systems. The community is also discussing the ambitious performance-based compensation package for Elon Musk, tying his compensation to aggressive milestones in robotics and AI, while some express concern over Elon Musk's renewed engagement in political matters and its potential impact on the brand.

Biggie is a popular Pitbull across several social media platforms, such as Tiktok, Youtube and Instagram. With a blend of creativity and comedic gestures, Biggie brings animal loving entertainment to millions of viewers through images, videos and reels. With Biggie the Pitbull's growing popularity, the meme coin $BIGGIE was inspired and launched on the ethereum network, leveraging Biggies unique sense of humor and style.

Biggie

Biggie crypto is trending, with community members discussing where to purchase it and its potential. Some users suggest the increase in attention could lead to further movement, while others believe there may be bot activity.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending as traders debate whether natural gas can sustain its recent gains amid mixed signals, including high storage levels and fluctuating weather forecasts. Community members are closely watching technical indicators and storage reports, with some expressing skepticism about the rally's longevity while others anticipate a winter squeeze. Discussions also involve the impact of LNG exports and potential production changes on the overall supply picture.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around this Solana-based meme coin, which is built on a joke. The project is focused on charitable donations, particularly to animal shelters, and boasts a strong, active community. Talk centers around its potential for growth within the dog-themed crypto space and recent listing on Jupiter Exchange.

Pump.fun

$PUMP.X is trending as traders discuss its potential as a leading platform in the memecoin space, with some drawing comparisons to the early days of Dogecoin. Community members are actively speculating on potential price targets and future exchange listings, while also debating the merits of its underlying platform.

Airship AI Holdings, Inc. engages in a video, sensor, and data management surveillance platform which focuses on the provision of software services. Its products include Airship Acropolis OS, Airship Command, and Airship Outpost. The company was founded by Derek Xu on June 30, 2003 and is headquartered in Redmond, WA.

Airship AI Holdings Inc - Ordinary Shares - Class A

AISP is trending amid discussions of government contracts and potential benefits from the "Big Beautiful Bill," particularly regarding border security and AI initiatives. The community is actively debating the stock's valuation, potential for a short squeeze, and the significance of insider buying, while awaiting news of contract awards. Some investors are speculating on a potential acquisition, and the warrants are seen as undervalued.

PolySwarm

PolySwarm is gaining attention as traders speculate on a potential breakout, fueled by rising volume and discussions around cybersecurity's growing importance. Community members are closely watching for a catalyst that could trigger a significant price movement, with some pointing to the upcoming week as a potentially volatile period for altcoins. Bullish sentiment is building, centered around the token's utility and the anticipation of a substantial pump.

What is the project about? The Helium Network is a decentralized, blockchain-based wireless infrastructure project that allows individuals and organizations to deploy and operate wireless networks through token incentivization. It leverages the Solana Blockchain for its foundation. The primary token powering the network is HNT, while IOT and MOBILE tokens are used to facilitate the LoRaWAN and 5G networks, respectively.  What makes your project unique? Decentralized Infrastructure: The Helium Network allows for the creation and maintenance of a distributed wireless network by incentivizing participants to contribute resources and share the benefits. Scalable and Secure: The network leverages the Solana Blockchain, which is known for its high scalability, low latency, and robust security. Multi-Use Case Support: The Helium Network supports various use cases, including IoT devices through the LoRaWAN network and high-speed mobile connectivity via the 5G network. Incentivized Participation: The Helium Network employs a token-based system to reward participants and encourage network growth. Proof-of-Coverage (PoC): A unique consensus algorithm employed by the LoRaWAN and 5G subnetworks, which rewards participants for verifying wireless network coverage.  What’s next for your project? Today, the Helium Network is a rapidly growing decentralized wireless infrastructure with a global footprint. It continues to attract new users, developers, and organizations, paving the way for innovative applications and services. As the network expands, it aims to revolutionize the wireless communication landscape and further democratize access to connectivity  What can your token be used for? The MOBILE token is the Governance token of the 5G Subnetworks, mined by 5G Hotspots through both data transfer proceeds as well as Proof of Coverage.

Helium Mobile

Helium Mobile ($MOBILE.X) is trending amid discussions about its future utility and potential for price movement, with some traders hoping for a pump. The community is actively debating the impact of past events such as Coinbase delisting, and whether MOBILE will follow Helium ($HNT.X) in a potential rally. Some users highlight ongoing partnerships, while others express concerns about its long-term value.

Oscar is a famous meme featuring a Shiba on a trampoline that went viral on the internet. It was also the first meme Ryoshi used when he introduced the Shiba Inu token to the world in the well-known Medium article titled All Hail The Shiba! (August 2, 2020).  Oscar appears in this article, with Ryoshi himself commenting, “Next we tell some more frens and WOW MOON LAMBO PUMPPPPPPY." Many might say this was Ryoshi’s own prophecy, predicting that Oscar would one day come into existence.  Now, Oscar is a CTO token embraced and guided by the Shiba community, and it also enjoys the support of Paradox Designer. Paradox was alongside Ryoshi from day one of the Shiba Inu token's creation, playing a crucial role in its success as the first member in Ryoshi’s Telegram group and also on Discord. Moreover, Paradox Designer is the artist behind the iconic Shiba Inu token logo, which is now recognized and famous worldwide.

OSCAR

$OSCAR.X is trending as the community focuses on its mission to feed stray dogs and build a 'crypto for good' ecosystem on the Ethereum and Shibarium blockchains. Community members highlight the project's roots as the original Shiba Inu meme and its ongoing development of DeFi utilities like staking for $COLLAR. The recent buzz is around its charity initiatives and the ability to make a tangible impact with micro-donations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street issued mixed calls on scPharmaceuticals on Monday after MannKind said it would buy the former in a deal that could total $360 million, or approximately $6.35 per share if all milestones are met.&nbsp;The deal represents a 31% premium to scPharma’s last closing price before the announcement.After the news, Craig-Hallum pulled back its rating on scPharmaceuticals, shifting it from ‘Buy’ to ‘Hold’ and setting a price target of $6.&nbsp;Craig-Hallum noted that shareholders are entitled to receive $5.35 in cash per share, along with the potential to receive up to an additional $1 in cash per share from future milestone payments and the firm expects a majority of the CVR value to be paid out over time.Maxim Group also downgraded scPharmaceuticals to ‘Hold’ from ‘Buy’ following the acquisition agreement under the same terms.By contrast, H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with a $9 price target, saying the acquisition strengthens MannKind’s revenue base and expands its reach into cardiorenal medicine. The firm described the price paid as “very reasonable.”The acquisition gives&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-corporation-to-acquire-scpharmaceuticals/chssVp5Rd1m">MannKind access to Furoscix</a>, scPharma’s FDA-approved on-body infuser delivering furosemide to treat fluid overload in patients with chronic heart failure and chronic kidney disease.&nbsp;MannKind estimates Furoscix has a total addressable U.S. market of more than $10 billion.scPharma has been expanding its commercial footprint, reporting $27.8 million in net sales for the first half of 2025, a 96% increase year over year, driven by a larger sales force, growth in nephrology, and new integrated delivery network accounts.&nbsp;Its Furoscix ReadyFlow Autoinjector is expected to be filed for FDA approval in the third quarter of 2025, potentially reducing administration time from five hours to less than 10 seconds.The deal is expected to close in the fourth quarter of 2025 pending regulatory approval.&nbsp;At closing, MannKind will also repay and retire scPharma’s credit facility and revenue-sharing obligations to Perceptive, totaling about $81 million if completed by Sept. 30, 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.On Stocktwits, retail sentiment was ‘extremely bullish’ for scPharmaceuticals with ‘extremely high’ message volume, while sentiment for MannKind was ‘bullish’ with ‘high’ message volume.One user remarked that it was unusual to see a smaller company like MannKind buying a larger one, calling the deal “bizarro territory.”<stembedurl>https://stocktwits.com/Kuka/message/626521368</stembedurl>Another user noted that the acquisition would eliminate scPharmaceuticals’ heavy sales and marketing costs, saying they were beginning to appreciate the efficiency gains MannKind could achieve by folding those operations into its own.<stembedurl>https://stocktwits.com/oneyedjacks/message/626485594</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SCPH">scPharmaceuticals’ stock</a> has risen nearly 56% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined nearly 40% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MannKind (MNKD) said it would buy scPharmaceuticals (SCPH) in a deal that could total $360 million, or approximately $6.35 per share if all milestones are met. (Photo credit: Getty Images)

MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish

The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.

Equity

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.Under the merger agreement, MannKind will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals common stock for $5.35 per share in cash at closing, in addition to one contingent value right worth up to $1. The non-tradeable CVR is payable upon achieving certain regulatory and net sales milestones, the companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-acquire-scpharmaceuticals-accelerating-revenue-growth">said</a>.The total per-share consideration of up to $6.35 represents a premium of about 31% to SCPH’s closing price on Friday. The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MannKind</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/SCPH">SCPH stock</a> jumped from ‘neutral’ to ‘bullish’ territory, accompanied by ‘low’ levels of retail chatter. While shares of MannKind traded 5% lower in the pre-market session, SCPH stock traded 13% higher.scPharmaceuticals currently markets Furoscix, an FDA-approved on-body infuser delivering Furosemide, used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD). MannKind, which estimates Furoscix has a total addressable market of over $10 billion in the U.S., said that the acquisition will expand its reach into cardiorenal medicine.MannKind also stated that the combined company is expected to have a stronger revenue base with three commercial assets, including Furoscix.While MNKD stock is down by 36% this year, SCPH stock is up by 37%.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-stock-sees-retail-chatter-spike-340-ahead-of-earnings/chssFwcRd1Y">Alibaba Stock Sees Retail Chatter Spike 340% Ahead Of Earnings: AI Investment And E-Commerce In Focus</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

MannKind Corporation to Acquire scPharmaceuticals: More Details Inside

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.

The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -13.33% and -2.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of +150.00% and -3.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

scPharmaceuticals's Earnings Outlook

Buy Rating Affirmed: scPharmaceuticals's Revenue Surge and Product Development Promise

Maxim Group analyst Naz Rahman reiterated a Buy rating on scPharmaceuticals (SCPH Research Report) yesterday and set a price target of $20.00. Na...

Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization

FDA approves scPharmaceuticals' expanded Furoscix indication to include NYHA Class IV heart failure patients. scPharmaceuticals secures $125M non-dilutive financing to repay debt and advance...

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The firm's products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Current Price	$5.63
Prev Close	$5.63
Open	$5.62
Dividend Yield	0.00%
50-Day Moving Average	$5.04
Beta	1.07
Avg. Volume	1.98M
PE Ratio	-3.11

52-Week High	$6.28
52-Week Low	$1.94
Market Capitalization	$302.21M
EPS (Annual)	-$1.91
Price to Book	-14.07
Revenue Per Employee	$221,536.58
Enterprise Value/EBITDA	N/A

SCPH
scPharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SCPH News

SCPH scPharmaceuticals Inc